Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study

PLoS ONE

Volumn 13, Issue 4, 2018, Pages

  Logviss, Konstantins ^a   Krievins, Dainis ^b,c   Purvina, Santa ^a  

^a RIGA STRADINS UNIVERSITY   (Latvia)

^b PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^c UNIVERSITY OF LATVIA   (Latvia)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

ANONYMIZATION; ARTICLE; CLINICAL EVALUATION; CLINICAL STUDY; COMMON DISEASE; COMPARATIVE STUDY; DATA ANALYSIS; DISEASES; EUROPE; EVIDENCE BASED PRACTICE; HUMAN; LATVIA; OVERALL SURVIVAL; RANDOMIZATION; RARE DISEASE; STUDY DESIGN; CLINICAL TRIAL (TOPIC); EPIDEMIOLOGY; META ANALYSIS; OUTCOME ASSESSMENT; PROCEDURES; REGISTER; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

CLINICAL TRIALS AS TOPIC; HUMANS; LATVIA; OUTCOME ASSESSMENT (HEALTH CARE); RARE DISEASES; REGISTRIES; SURVIVAL RATE;

EID: 85045008728     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0194494     Document Type: Article

References (33)

1. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Off J Eur Communities. 2000; L18:1-5. Available from: Http://eur-lex. europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF.
2. Council recommendation of 8 June 2009 on an action in the field of rare diseases. Off J Eur Union. 2009; C151:7-10. Available from: Http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ: C:2009:151:0007:0010:EN:PDF.
3. Kakkis ED, O'Donovan M, Cox G, Hayes M, Goodsaid F, Tandon PK, et al. Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints. Orphanet J Rare Dis. 2015; 10:16. https://doi.org/10.1186/s13023-014-0195-4 PMID: 25757705
4. Buckley BM. Clinical trials of orphan medicines. Lancet. 2008; 371:2051-5. https://doi.org/10.1016/ S0140-6736(08)60876-4 PMID: 18555919
5. Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, et al. Clinical research for rare disease: Opportunities, challenges, and solutions. Mol Genet Metab. 2009; 96(1):20-6. https://doi. org/10.1016/j.ymgme.2008.10.003 PMID: 19013090
6. Gagne JJ, Thompson L, O'Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: Methodological review. BMJ. 2014; 349:g6802. https://doi.org/10.1136/bmj. g6802 PMID: 25422272
7. Richey EA, Lyons EA, Nebeker JR, Shankaran V, McKoy JM, Luu TH, et al. Accelerated approval of cancer drugs: Improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?. J Clin Oncol. 2009; 27(26):4398-405. https://doi.org/10.1200/JCO.2008.21.1961 PMID: 19636013
8. Mitsumoto J, Dorsey ER, Beck CA, Kieburtz K, Griggs RC. Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol. 2009; 66(2):184-90. https://doi.org/10.1002/ana.21676 PMID: 19743448
9. Joppi R, Bertele V, Garattini S. Orphan drug development is not taking off. Br J Clin Pharmacol. 2009; 67(5):494-502. https://doi.org/10.1111/j.1365-2125.2009.03369.x PMID: 19552743
10. Onakpoya IJ, Spencer EA, Thompson MJ, Heneghan CJ. Effectiveness, safety and costs of orphan drugs: An evidence-based review. BMJ Open. 2015; 5:e007199. https://doi.org/10.1136/bmjopen-2014-007199 PMID: 26109112
11. Winstone J, Chadda S, Ralston S, Sajosi P. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments. Orphanet J Rare Dis. 2015; 10:139. https://doi.org/10.1186/s13023-015-0349-z PMID: 26511061
12. Joppi R, Bertele V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol. 2013; 69:1009-24. https://doi.org/10.1007/s00228-012-1423-2 PMID: 23090701
13. Picavet E, Cassiman D, Hollak CE, Maertens JA, Simoens S. Clinical evidence for orphan medicinal products - A cause for concern?. Orphanet J Rare Dis. 2013; 8:164. https://doi.org/10.1186/1750-1172-8-164 PMID: 24131572
14. Kanters TA, de Sonneville-Koedoot C, Redekop WK, Hakkaart L. Systematic review of available evidence on 11 high-priced inpatient orphan drugs. Orphanet J Rare Dis. 2013; 8:124. https://doi.org/10. 1186/1750-1172-8-124 PMID: 23947946
15. Dupont AG, Van Wilder PB. Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol. 2011; 71(4):488-96. https://doi.org/10.1111/j.1365-2125.2010.03877.x PMID: 21395641
16. Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: An analysis of ClinicalTrials.gov. Orphanet J Rare Dis. 2014; 9:170. https://doi.org/10.1186/s13023-014-0170-0 PMID: 25427578
17. Logviss K, Krievins D, Purvina S. Impact of orphan drugs on Latvian budget. Orphanet J Rare Dis. 2016; 11:59. https://doi.org/10.1186/s13023-016-0434-y PMID: 27169704
18. Meekings KN, Williams CSM, Arrowsmith JE. Orphan drug development: An economically viable strategy for biopharma R&D. Drug Discov Today. 2012; 17(13/14):660-4.
19. Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA. 2011; 305(22):2320-6. https://doi.org/10.1001/jama.2011.769 PMID: 21642684
20. Orfali M, Feldman L, Bhattacharjee V, Harkins P, Kadam S, Lo C, et al. Raising orphans: How clinical development programs of drugs for rare and common diseases are different. Clin Pharmacol Ther. 2012; 92(2):262-4. https://doi.org/10.1038/clpt.2012.87 PMID: 22739137
21. Mechler K, Mountford WK, Hoffmann GF, Ries M. Pressure for drug development in lysosomal storage disorders - A quantitative analysis thirty years beyond the US orphan drug act. Orphanet J Rare Dis. 2015; 10:46. https://doi.org/10.1186/s13023-015-0262-5 PMID: 25896727
22. Heemstra HE, Leufkens HG, Rodgers RP, Xu K, Voordouw BC, Braun MM. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. Drug Discov Today. 2011; 16(1/ 2):73-80.
23. Guideline on clinical trials in small populations. Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency (EMA). 2006. Available from: Http://www.ema.europa.eu/docs/ en-GB/document-library/Scientific-guideline/2009/09/WC500003615.pdf.
24. Miyamoto BE, Kakkis ED. The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Orphanet J Rare Dis. 2011; 6:49. https://doi.org/10.1186/1750-1172-6-49 PMID: 21733145
25. Logviss K, Krievins D, Purvina S. Rare diseases and orphan drugs: Latvian story. Orphanet J Rare Dis. 2014; 9:147. https://doi.org/10.1186/s13023-014-0147-z PMID: 25231378
26. Choice of control group in clinical trials. ICH topic E10. European Medicines Agency (EMA). 2001. Available from: Http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/ WC500002925.ppd.
27. Spokiene I. Legal assessment of current situation on orphan patients in Lithuania. Medicina (Kaunas). 2008; 44(8):571-6.
28. Tuberculosis surveillance and monitoring in Europe 2016. Surveillance report. European Centre for Disease Prevention and Control (ECDC) andWHORegional Office for Europe. 2016. Available from: Http:// ecdc.europa.eu/en/publications/Publications/ecdc-tuberculosis-surveillance-monitoring-Europe-2016.pdf.
29. Hee SW, Willis A, Tudur Smith C, Day S, Miller F, Madan J, et al. Does the low prevalence affect the sample size of interventional clinical trials of rare diseases?. An analysis of data from the aggregate analysis of clinicaltrials.gov. Orphanet J Rare Dis. 2017; 12:44. https://doi.org/10.1186/s13023-017-0597-1 PMID: 28253932
30. Unkel S, Röver C, Stallard N, Benda N, Posch M, Zohar S, Friede T. Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. Orphanet J Rare Dis. 2016; 11:16. https://doi.org/10.1186/s13023-016-0402-6 PMID: 26897367
31. Abrahamyan L, Diamond IR, Johnson SR, Feldman BM. A new toolkit for conducting clinical trials in rare disorders. J Popul Ther Clin Pharmacol. 2014; 21(1):e66-78. PMID: 24671886
32. Maeda H, Kurokawa T. Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency. Ann Oncol. 2015; 26(1):211-6. https://doi.org/ 10.1093/annonc/mdu500 PMID: 25361994
33. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Communities. 2001; L121:34-44. Available from: Http://ec.europa.eu/health/files/eudralex/ vol-1/dir-2001-20/dir-2001-20-en.pdf.